Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring

作者：Marengo M F; Waimann C A; de Achaval S; Zhang H; Garcia Gonzalez A; Richardson M N; Reveille J D; Suarez Almazor M E^*

来源：Lupus, 2012, 21(11): 1158-1165.

DOI：10.1177/0961203312447868

• Treatment adherence
• electronic monitoring
• systemic lupus erythematosus
• outcomes

Objective: We used an electronic monitoring system to quantify adherence to prescribed oral therapies by patients with systemic lupus erythematosus (SLE). Methods: Participants were included from a larger longitudinal study cohort of 110 patients recruited from publicly-funded rheumatology clinics, 78 of whom agreed to have their SLE drug therapy electronically monitored for two years with the Medication Events Monitoring System (MEMS (R), AARDEX Group). Adherence was determined as the percentage of days (weeks for methotrexate) the patient took the medication as prescribed by the physician. Collected data included SLEDAI; SLICC damage index for SLE (SDI); medical outcome study social support survey (MOS-SSS); Center for Epidemiologic Studies depression scale (CESD); and quality of life (SF-12). Results: Ninety percent of the cohort was female, 45% were Hispanic, and 49% were African-American. Mean age was 36.3 years, disease duration was 5.9 years, SLEDAI score was 3.2, and SDI score was 0.9. Adherence was 62% for all drugs combined and did not differ significantly for individual medications. Patients with more depression (p %26lt; 0.02), and higher number of pills taken daily (p %26lt; 0.02) were more likely to be non-adherent. Only one-fourth of the patients had an average adherence of %26gt;= 80%; these patients had a better mental component score (SF-12) at 24 months than non-adherent patients (p %26lt; 0.01). Conclusions: Electronic monitoring demonstrated that only one-fourth of the patients had an adherence rate %26gt;= 80%. Polypharmacy and depression were associated with non-adherence. Lupus (2012) 21, 1158-1165.

• 出版日期2012-10